{
  "content": "Diagnosis\n\t1. Descending colon adenocarcinoma, micropapillary subtype\n\tInitially pT3N1M0 at diagnosis January 2023\n\tProgressed with liver and bone metastases March 2024\n\tKRAS G12C mutation positive, BRAF wild-type\n\n\tTreatment aim\n\tDisease control\n\n\tSummary of completed treatment and relevant dates\n\n\tSurgery\n\t15 Jan 2023 Left hemicolectomy\n\n\tChemotherapy\n\t1. Feb-July 2023: Adjuvant CAPOX - 8 cycles completed\n\t2. March 2024: FOLFIRI - discontinued after 2 cycles due to progression\n\n\tClinical studies\n\tADORA-2 Phase II trial of MRTX849 (KRAS G12C inhibitor)\n\tCommenced 15 April 2024\n\n\tCurrent disease status\n\tStable disease on first assessment\n\n\tCurrent issues\n\tGrade 2 diarrhea\n\tMild fatigue\n\n\tSummary of consultation\n\tReviewed today for cycle 3, day 1 of MRTX849 on the ADORA-2 trial. First radiological assessment completed on 20 May 2024 shows stable disease by RECIST 1.1 criteria with no new lesions identified. The largest liver metastasis in segment 7 measures 3.2cm (previously 3.3cm) and bone lesions are stable.\n\nTolerating treatment relatively well with grade 2 diarrhea managed with loperamide as needed. Reports 4-5 loose stools daily, improved from 6-7 at last review. Fatigue is mild and not impacting daily activities. No other significant toxicities noted.\n\nTrial-mandated blood tests, ECG, and vital signs all within acceptable parameters. Performance status remains 1.\n\n\tFurther investigations\n\tNext trial-mandated CT chest/abdomen/pelvis due 15 July 2024\n\tMonthly ECG monitoring as per protocol\n\n\tMedication prescribed\n\tMRTX849 600mg twice daily to continue\n\tLoperamide 2mg prn for diarrhea\n\n\tFollow up\n\tNext trial assessment in 2 weeks\n\tCT assessment in 8 weeks\n\n\tRequired trial protocol actions\n\tQuality of life questionnaires completed\n\tAdverse event documentation updated\n\tTrial medication diary reviewed and compliance confirmed\n\n\tSummary of information given to patient\n\tDiscussed stable disease status on first assessment\n\tReviewed management strategy for diarrhea\n\tProvided next appointment schedule",
  "output": {
    "primary_cancer": {
      "site": "descending colon",
      "year": 2023,
      "month": 1,
      "metastases": "liver and bone metastases",
      "tnm_stage": "pT3N1M0",
      "histopathology_status": "micropapillary adenocarcinoma",
      "biomarker_status": "KRAS G12C mutation positive, BRAF wild-type",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Left hemicolectomy",
          "year": 2023,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started adjuvant CAPOX chemotherapy",
          "year": 2023,
          "month": 2
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed 8 cycles of adjuvant CAPOX",
          "year": 2023,
          "month": 7
        },
        {
          "type": "anatomical_finding",
          "value": "Disease progression with new liver and bone metastases",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started FOLFIRI chemotherapy",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Discontinued FOLFIRI after 2 cycles due to progression",
          "year": 2024,
          "month": 3
        },
        {
          "type": "clinical_trial_update",
          "value": "Commenced ADORA-2 trial with MRTX849 (KRAS G12C inhibitor)",
          "year": 2024,
          "month": 4
        },
        {
          "type": "anatomical_finding",
          "value": "CT assessment shows stable disease by RECIST 1.1 criteria, largest liver metastasis 3.2cm (previously 3.3cm), stable bone lesions",
          "year": 2024,
          "month": 5
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "Performance status 1"
      },
      {
        "type": "current_symptom",
        "value": "4-5 loose stools daily"
      },
      {
        "type": "current_symptom",
        "value": "Mild fatigue not impacting daily activities"
      },
      {
        "type": "investigation_finding",
        "value": "Trial-mandated blood tests and ECG within acceptable parameters"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic colon cancer with liver and bone involvement, showing stable disease on KRAS G12C inhibitor trial therapy"
      },
      {
        "type": "latest_treatment_response",
        "value": "Stable disease on first assessment with minimal change in measurable disease"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Grade 2 diarrhea managed with loperamide, improved from 6-7 to 4-5 stools daily"
      },
      {
        "type": "update_to_treatment",
        "value": "Continuing MRTX849 600mg twice daily with good compliance"
      },
      {
        "type": "planned_investigation",
        "value": "Next trial-mandated CT chest/abdomen/pelvis due 15 July 2024"
      },
      {
        "type": "follow_up_referral",
        "value": "Next trial assessment in 2 weeks"
      }
    ]
  }
}